[go: up one dir, main page]

WO2011080271A3 - Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof - Google Patents

Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof Download PDF

Info

Publication number
WO2011080271A3
WO2011080271A3 PCT/EP2010/070800 EP2010070800W WO2011080271A3 WO 2011080271 A3 WO2011080271 A3 WO 2011080271A3 EP 2010070800 W EP2010070800 W EP 2010070800W WO 2011080271 A3 WO2011080271 A3 WO 2011080271A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasmodium
obtaining
exosomes
reticulocytes
infected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/070800
Other languages
French (fr)
Other versions
WO2011080271A2 (en
Inventor
Hernando Antonio Del Portillo Obando
Lorena Martin Jaular
María Carmen DEL FERNANDEZ BECERRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE DE RECERCA EN SALUT INTERNACIONAL DE BARCELONA
Fundacio Cellex
Institucio Catalana de Recerca i Estudis Avancats ICREA
Hospital Clinic de Barcelona
Original Assignee
CENTRE DE RECERCA EN SALUT INTERNACIONAL DE BARCELONA
Fundacio Cellex
Institucio Catalana de Recerca i Estudis Avancats ICREA
Hospital Clinic de Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRE DE RECERCA EN SALUT INTERNACIONAL DE BARCELONA, Fundacio Cellex, Institucio Catalana de Recerca i Estudis Avancats ICREA, Hospital Clinic de Barcelona filed Critical CENTRE DE RECERCA EN SALUT INTERNACIONAL DE BARCELONA
Priority to JP2012546436A priority Critical patent/JP2013515495A/en
Priority to EP10800764.2A priority patent/EP2519254B1/en
Priority to US13/519,527 priority patent/US8790661B2/en
Priority to AU2010338274A priority patent/AU2010338274A1/en
Priority to BR112012016048A priority patent/BR112012016048A2/en
Priority to CN2010800648419A priority patent/CN102844046A/en
Publication of WO2011080271A2 publication Critical patent/WO2011080271A2/en
Publication of WO2011080271A3 publication Critical patent/WO2011080271A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

The present invention belongs to the field of vaccines for the prevention and prophylaxis against malaria, more specifically it relates to exosomes isolated from reticulocytes infected with Plasmodium sp., to methods for obtaining them and to the use thereof for the prevention and prophylaxis against malaria as well as to its use for the discovery and identification of novel Plasmodium antigens. The invention also refers to artificial exosomes comprising Plasmodium sp. antigens. Finally, the invention refers to specific antigens discovered by means of the exosomes obtained from reticulocytes infected with Plasmodium sp.
PCT/EP2010/070800 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof Ceased WO2011080271A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2012546436A JP2013515495A (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with Plasmodium species, methods for obtaining them and uses thereof
EP10800764.2A EP2519254B1 (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
US13/519,527 US8790661B2 (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with Plasmodium sp., method for obtaining them and uses thereof
AU2010338274A AU2010338274A1 (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with Plasmodium sp., method for obtaining them and uses thereof
BR112012016048A BR112012016048A2 (en) 2009-12-28 2010-12-28 "plasmodium sp. infected reticulocyte derived exosomes, method of obtaining them and uses thereof".
CN2010800648419A CN102844046A (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931275A ES2362589B1 (en) 2009-12-28 2009-12-28 EXOSOMES DERIVED FROM RETICULOCITS INFECTED WITH PLASMODIUM SP., METHOD FOR OBTAINING AND USE.
ESP200931275 2009-12-28

Publications (2)

Publication Number Publication Date
WO2011080271A2 WO2011080271A2 (en) 2011-07-07
WO2011080271A3 true WO2011080271A3 (en) 2012-01-05

Family

ID=44121766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/070800 Ceased WO2011080271A2 (en) 2009-12-28 2010-12-28 Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof

Country Status (8)

Country Link
US (1) US8790661B2 (en)
EP (1) EP2519254B1 (en)
JP (1) JP2013515495A (en)
CN (1) CN102844046A (en)
AU (1) AU2010338274A1 (en)
BR (1) BR112012016048A2 (en)
ES (1) ES2362589B1 (en)
WO (1) WO2011080271A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI582232B (en) 2013-03-13 2017-05-11 Zhong Li Microbubbles and methods for their manufacture
US10987432B2 (en) 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
RU2556825C1 (en) * 2014-09-15 2015-07-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Method of extraction of exosomes from blood
JP2017101012A (en) * 2015-11-30 2017-06-08 義之 小山 Immunotherapy preparation
CN108066361A (en) * 2017-01-23 2018-05-25 广州中科蓝华生物科技有限公司 A kind of excretion body, its preparation method and its purposes in anti-tumor drug or preparation is prepared
CN107056920B (en) * 2017-05-23 2020-05-12 中国医科大学 Application of recombinant protein rPgmp22 of plasmodium berghei gametophyte in malaria transmission blocking
CN107176991B (en) * 2017-05-23 2020-05-12 中国医科大学 Application of a recombinant Plasmodium berghei gametophyte protein rPbG37 in blocking malaria transmission
US20210355492A1 (en) * 2018-09-21 2021-11-18 City University Of Hong Kong Cargo loaded extracellular vesicles
CN115120714A (en) * 2021-03-29 2022-09-30 华中科技大学 Immune preparation, composition containing immune preparation, application of immune preparation and preparation method of immune preparation
CN113144222B (en) * 2021-04-14 2023-05-23 台州学院 Experimental method for preventing cerebral malaria by exosomes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070418A1 (en) * 2004-01-21 2005-08-04 M N L Pharma Limited Immunomodulatory alkaloids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
FR2766205B1 (en) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
FR2785543B1 (en) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med MODIFIED EXOSOMES AND USES
KR100519384B1 (en) 2002-08-13 2005-10-06 (주)누백스 Manufacturing method of exosomes using gene transfection and use of the same
CN101641010A (en) * 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 Modification of exosome components for use as vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070418A1 (en) * 2004-01-21 2005-08-04 M N L Pharma Limited Immunomodulatory alkaloids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ESPOSITO F ET AL: "Intraerythrocytic administration of a synthetic Plasmodium antigen elicits antibody response in mice, without carrier molecules or adjuvants", INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 20, no. 8, 1 December 1990 (1990-12-01), pages 1109 - 1111, XP023651736, ISSN: 0020-7519, [retrieved on 19901201], DOI: DOI:10.1016/0020-7519(90)90059-V *
FERNANDEZ-BECERRA C ET AL: "Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily", TRENDS IN PARASITOLOGY, ELSEVIER CURRENT TRENDS, GB, vol. 25, no. 1, 1 January 2009 (2009-01-01), pages 44 - 51, XP025866277, ISSN: 1471-4922, [retrieved on 20081125], DOI: DOI:10.1016/J.PT.2008.09.012 *
LI XIAOBO ET AL: "Nanovesicular vaccines: exosomes", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, BIRKHAEUSER VERLAG AG, CH, vol. 53, no. 4, 1 July 2005 (2005-07-01), pages 329 - 335, XP009149577, ISSN: 0004-069X *
RIBAUT CLOTILDE ET AL: "Concentration and purification by magnetic separation of the erythrocytic stages of all human Plasmodium species", MALARIA JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 5 March 2008 (2008-03-05), pages 45, XP021036583, ISSN: 1475-2875 *
SCHOREY JEFFREY S ET AL: "Exosome function: from tumor immunology to pathogen biology.", TRAFFIC (COPENHAGEN, DENMARK) JUN 2008 LNKD- PUBMED:18331451, vol. 9, no. 6, June 2008 (2008-06-01), pages 871 - 881, XP002644382, ISSN: 1600-0854 *

Also Published As

Publication number Publication date
AU2010338274A1 (en) 2012-07-19
WO2011080271A2 (en) 2011-07-07
US8790661B2 (en) 2014-07-29
ES2362589B1 (en) 2012-05-16
BR112012016048A2 (en) 2019-09-24
US20120321676A1 (en) 2012-12-20
EP2519254B1 (en) 2017-05-03
CN102844046A (en) 2012-12-26
JP2013515495A (en) 2013-05-09
EP2519254A2 (en) 2012-11-07
ES2362589A1 (en) 2011-07-08

Similar Documents

Publication Publication Date Title
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
PH12018500856A1 (en) Respiratory syncytial virus vaccine
EP4349405A3 (en) Respiratory virus vaccines
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
PH12013502442A1 (en) Inactivated dengue virus vaccine
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
WO2012134086A3 (en) Three-dimensional nanofiber scaffold for tissue repair and preparation method thereof
WO2010009879A3 (en) Methods for producing paricalcitol
WO2012165815A3 (en) Nano-vehicle derived from tumor tissue, and cancer vaccine using same
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
HK1254522A1 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
GEAP201913226A (en) Hyr1-derived compositions and methods of treatment using same
WO2012047582A3 (en) Compositions useful for target, detection, imaging and treatment, and methods of production and use thereof
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
PL2855513T3 (en) Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
WO2013026452A9 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
WO2012048033A3 (en) Novel compositions for inhibiting virus entry and promoting virolyisis, and methods thereof
WO2011027359A3 (en) Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080064841.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800764

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012546436

Country of ref document: JP

Ref document number: 2010338274

Country of ref document: AU

Ref document number: 1630/MUMNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010338274

Country of ref document: AU

Date of ref document: 20101228

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2010800764

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010800764

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13519527

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012016048

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012016048

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120628